ATE365554T1 - Methode zur behandlung von erkrankungen der unteren harnwege - Google Patents

Methode zur behandlung von erkrankungen der unteren harnwege

Info

Publication number
ATE365554T1
ATE365554T1 AT04758741T AT04758741T ATE365554T1 AT E365554 T1 ATE365554 T1 AT E365554T1 AT 04758741 T AT04758741 T AT 04758741T AT 04758741 T AT04758741 T AT 04758741T AT E365554 T1 ATE365554 T1 AT E365554T1
Authority
AT
Austria
Prior art keywords
urinary
symptom
sub
subject
urinary tract
Prior art date
Application number
AT04758741T
Other languages
German (de)
English (en)
Inventor
Steven Landau
Cheryl Miller
Matthew Fraser
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE365554T1 publication Critical patent/ATE365554T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT04758741T 2003-04-04 2004-04-02 Methode zur behandlung von erkrankungen der unteren harnwege ATE365554T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46102203P 2003-04-04 2003-04-04
US49650203P 2003-08-20 2003-08-20
US53634104P 2004-01-13 2004-01-13

Publications (1)

Publication Number Publication Date
ATE365554T1 true ATE365554T1 (de) 2007-07-15

Family

ID=33162987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04758741T ATE365554T1 (de) 2003-04-04 2004-04-02 Methode zur behandlung von erkrankungen der unteren harnwege

Country Status (9)

Country Link
US (5) US6846823B2 (https=)
EP (1) EP1539181B1 (https=)
JP (1) JP2006522144A (https=)
AT (1) ATE365554T1 (https=)
AU (1) AU2004227945B2 (https=)
CA (1) CA2519379A1 (https=)
DE (1) DE602004007225T2 (https=)
ES (1) ES2290741T3 (https=)
WO (1) WO2004089288A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7085845B2 (en) * 2001-05-09 2006-08-01 Gene Fein Method, apparatus and computer program product for identifying a playing media file and tracking associated user preferences
CN100355419C (zh) * 2002-06-07 2007-12-19 安斯泰来制药有限公司 治疗膀胱过度活动的药物
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
JP5548329B2 (ja) * 2003-08-04 2014-07-16 杏林製薬株式会社 経皮吸収型製剤
EP1727527A1 (en) * 2004-03-19 2006-12-06 Solvay Pharmaceuticals GmbH Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
CA2580170A1 (en) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract
US7985736B2 (en) * 2004-12-14 2011-07-26 The John Hopkins University High throughput screen utilizing newly discovered intramolecular neuronal calcium channel interactions to discover new analgesics
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
KR20140002082A (ko) * 2005-01-14 2014-01-07 유리젠, 인코포레이티드 하부 요로 장애 치료용 키트 및 개선된 조성물
EP1855680A2 (en) * 2005-02-25 2007-11-21 Solvay Pharmaceuticals, Inc. Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US20070093520A1 (en) * 2005-04-15 2007-04-26 Caras Steven D Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US20070172508A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
US20070172507A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
US20070244143A1 (en) * 2006-03-08 2007-10-18 Braincells, Inc Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US7975699B2 (en) * 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
EP1997807A1 (en) * 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
CA2673545A1 (en) * 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20090274722A1 (en) * 2007-01-29 2009-11-05 Ligums John E Therapeutic Composition for the Treatment of BPH and ED
EP2136863A2 (en) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
CN104069567A (zh) * 2007-03-19 2014-10-01 茵苏莱恩医药有限公司 药物输送设备
BRPI0812000A2 (pt) * 2007-05-30 2014-11-18 Microdose Therapeutx Inc Métodos e composições para administração de oxibutinina
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US10080823B2 (en) * 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US20110182970A1 (en) * 2007-10-30 2011-07-28 Hyde Roderick A Nitric oxide sensors and systems
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
AU2009312474B2 (en) 2008-11-07 2014-12-04 Insuline Medical Ltd. Device and method for drug delivery
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
CN105381524A (zh) 2010-01-05 2016-03-09 微剂量治疗技术公司 吸入设备和方法
US10238821B2 (en) 2016-10-11 2019-03-26 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2020030777A1 (en) * 2018-08-10 2020-02-13 Grünenthal GmbH Composition for treating urinary frequency and/or urinary urgency

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046489A (en) 1958-11-28 1962-07-24 Elcor Inc Wide band direct coupled amplifier
ES274725A1 (es) 1961-02-04 1962-06-16 Orlandi Giorgio Aparato de distanciamiento de filamentos, cordones y cintas de pasta alimenticia para hacer seguir a camaras y hornos de fermentaciën y cochura
JPS60146891A (ja) * 1984-01-05 1985-08-02 Mitsubishi Chem Ind Ltd 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩
DE3422155A1 (de) 1984-06-14 1985-12-19 Alfred Teves Gmbh, 6000 Frankfurt Hydraulische servofahrzeugbremse
EP0299053A1 (en) 1987-01-30 1989-01-18 American Home Products Corporation Des-epidermal growth factor plasminogen activators
DE3885357T2 (de) * 1987-06-29 1994-03-24 Duphar Int Res Anellierte Indolderivate.
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2044854A1 (en) * 1990-07-19 1992-01-20 Hong-I Chen Method for preventing or treating urinary incontinence
CA2061665C (en) * 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
JPH0616557A (ja) * 1992-12-21 1994-01-25 Mitsubishi Kasei Corp 脳機能障害改善剤
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
DK0855397T3 (da) * 1995-07-28 2001-06-25 Dainippon Pharmaceutical Co (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
PT975327E (pt) 1997-04-18 2003-11-28 Janssen Pharmaceutica Nv Uso de antagonistas de 5ht3 para estimular a lavagem intestinal
JPH10298078A (ja) 1997-05-06 1998-11-10 Mitsubishi Chem Corp 抗不安薬
DE19813661A1 (de) * 1997-08-01 1999-02-04 Solvay Pharm Gmbh Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron
DE19734444A1 (de) * 1997-08-08 1999-02-11 Basf Ag 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung
FR2781671A1 (fr) 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
EP1123923A4 (en) 1998-10-23 2002-11-27 Ajinomoto Kk DIHYDROPYRIDINE DERIVATIVES AND DRUG BLOCK CONTAINING THESE
US6272553B2 (en) * 1998-11-20 2001-08-07 Sprint Communications Company, L.P. Multi-services communications device
AU3422800A (en) 1999-02-18 2000-09-04 Novartis Ag Use of 5-ht3 receptor antagonists
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
DE19911371A1 (de) * 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
US6589570B1 (en) * 1999-04-12 2003-07-08 University Of Madras Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6846496B1 (en) * 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
WO2001051496A1 (en) * 2000-01-14 2001-07-19 Rhodia, Inc. Crosslinking agents for textile finishing baths
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
JP2002026134A (ja) * 2000-07-12 2002-01-25 Seiko Epson Corp 半導体集積回路の製造方法及びこの方法により製造した半導体集積回路
GB0112494D0 (en) 2001-05-22 2001-07-11 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
DE60312474T2 (de) 2002-01-18 2007-12-06 Aryx Therapeutics, Fremont 5-ht3-rezeptorantagonisten und verwendungsverfahren
GB0202265D0 (en) 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
CA2491836C (en) 2002-07-10 2011-01-25 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
BR0313836A (pt) 2002-08-29 2005-06-21 Arachnova Therapeutics Ltd Novos usos terapêuticos de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)tieno[2,3-d]pi rimidina
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
MXPA05007381A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
US7356884B2 (en) * 2003-12-18 2008-04-15 3M Innovative Properties Company Fastener for a display page

Also Published As

Publication number Publication date
EP1539181A4 (en) 2005-12-28
EP1539181B1 (en) 2007-06-27
ES2290741T3 (es) 2008-02-16
WO2004089288A3 (en) 2005-04-21
AU2004227945B2 (en) 2006-10-26
US20050020577A1 (en) 2005-01-27
EP1539181A2 (en) 2005-06-15
US20050282799A1 (en) 2005-12-22
US7115606B2 (en) 2006-10-03
JP2006522144A (ja) 2006-09-28
US6846823B2 (en) 2005-01-25
US20050026909A1 (en) 2005-02-03
DE602004007225D1 (de) 2007-08-09
US20040209869A1 (en) 2004-10-21
US20050272719A1 (en) 2005-12-08
WO2004089288A2 (en) 2004-10-21
DE602004007225T2 (de) 2008-03-06
AU2004227945A1 (en) 2004-10-21
CA2519379A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE365554T1 (de) Methode zur behandlung von erkrankungen der unteren harnwege
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2004062624A3 (en) Method of treating nausea, vomiting, retching or any combination thereof
WO2003047558A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
EA200600896A1 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
DE69826677D1 (de) Trizyclische vasopressin agoniste
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
SE0301883D0 (sv) New use II
SE0201939D0 (sv) New combination
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor
SE0100873D0 (sv) Method of treatment

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties